TOOKAD

This brand name is authorized in Austria, Estonia, Ireland, Lithuania, Poland

Active ingredients

The drug TOOKAD contains one active pharmaceutical ingredient (API):

1 Padeliporfin
UNII JQ72VD4XUL - PADELIPORFIN POTASSIUM

Padeliporfin is retained within the vascular system. When activated with 753 nm wavelength laser light, padeliporfin triggers a cascade of pathophysiological events resulting in focal necrosis within a few days.

Read about Padeliporfin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
TOOKAD Powder for solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01XD07 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XD Sensitizers used in photodynamic/radiation therapy
Discover more medicines within L01XD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1756807, 1756818
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1084469, 1084470
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100400647, 100400660

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.